Non-Fucosylated Anti-Human ACVR2B (ANB012) Therapeutic Antibody (CAT#: BioBet-513ZP) Datasheet

ACVR2B

activin A receptor, type IIB

Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptors are considered to be constitutively active kinases. This gene encodes activin A type IIB receptor, which displays a 3- to 4-fold higher affinity for the ligand than activin A type II receptor.

ACVR2B; activin A receptor, type IIB; HTX4; ACTRIIB; ActR-II

Plasma membrane

Diseases associated with ACVR2B include Heterotaxy, Visceral, 4, Autosomal and Heterotaxy.

Its related pathways are Signaling by NODAL and Signaling by GPCR.

The transmembrane serine/threonine kinase activin type 2 receptor and the activin type 1 serine/threonine kinase receptor (ACVR1, ACVR1B or ACVR1c) form an activin receptor complex. Transmit activin signals from the cell surface to the cytoplasm, thereby regulating many physiological and pathological processes, including neuronal differentiation and neuron survival, hair follicle development and circulation, FSH production by the pituitary, wound healing, extracellular matrix production, immunosuppression and carcinogenesis . It is also believed that activin has a paracrine or autocrine effect in the development of ovarian follicles. In the receptor complex, type 2 receptors act as the main activin receptors (combined with activin A/INHBA, activin B/INHBB, and inhibin A/INHA-INHBA). Type 1 receptors like ACVR1B act as downstream transducers of activin signaling. Activin binds to type 2 receptors on the plasma membrane and activates its serine-threonine kinase. Then, the activated type 2 receptor phosphorylates and activates the type 1 receptor. Once activated, type 1 receptors bind to and phosphorylate the SMAD proteins SMAD2 and SMAD3 on the serine residue at the C-terminal tail. Shortly after their binding to activin receptors and subsequent phosphorylation, SMAD2 and SMAD3 are released into the cytoplasm and interact with their co-partner SMAD4. The SMAD complex translocates into the nucleus and mediates activin-induced transcription. The inhibitory SMAD7 recruited to ACVR1B through FKBP1A prevents SMAD2 and SMAD3 from associating with the activin receptor complex, thereby blocking activin signaling. Activin signal transduction is also antagonized by the binding of the IGSF1 inhibin co-receptor to the inhibin B receptor.

1.Phosphorylated. Constitutive phosphorylation is in part catalyzed by its own kinase activity. 2.Modification sites at PhosphoSitePlus 3.Glycosylation at Asn42 and Asn65

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

ANB012

Human

Human

ANB012 is a pre-clinical antibody that antagonizes ActRIIB. ActRIIB antagonism has been shown to downregulate a variety of factors that lead to muscle loss and wasting.

Muscle loss and wasting

Muscle loss and wasting